Nouscom gains access to ProBioGen’s technology platform 26th June 2018
ProBioGen AG, a premier German service and technology provider for complex therapeutic glycoproteins, virus production and viral vector technologies, and Nouscom AG, an oncology company dedicated to development of immunotherapies, today jointly announced signing a license agreement. Under the terms of the agreement, Nouscom will gain access to ProBioGen’s proprietary production platform based on the AGE1.CR duck retina cell line for production of its viral vectored vaccines.
ProBioGen’s CSO, Dr Volker Sandig said, “We have developed the AGE1.CR designer cell line, the chemically defined media and the process over many years, aiming to overcome challenges in the production of highly attenuated poxvirus vectors. We are very pleased to see a strong industry demand for our platform and are convinced that Nouscom´s highly innovative vaccine approach will greatly benefit from it.”
Nouscom’s CTO, Dr Stefano Colloca added, “We are very pleased with this new partnership with ProBioGen which allows us to utilize a scalable GMP manufacturing process for production of our viral vectored vaccines. This is an important milestone in our journey towards becoming a clinical stage company.”